11 completed. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 9 |
| Phase 2 | 4 | Completed 4 |
Follow XL765: new trials by email Literature Review of XL765 trials Research Report on XL765
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Pimasertib once daily, Pimasertib placebo, SAR245409 placebo - Ovarian Cancer | Phase 2 | Completed | EMD Serono | 65 | 2013-09-30 | 2018-12-12 |
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen SAR245408, SAR245409 - Neoplasm Malignant | Phase 1 / Phase 2 | Completed | Sanofi | 61 | 2012-07-20 | 2022-04-19 |
| A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma SAR245409 - Neoplasm Malignant | Phase 1 | Completed | Sanofi | 49 | 2012-06-01 | 2020-10-28 |
| Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia SAR245409 - Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 1 | Completed | Sanofi | 37 | 2011-12-01 | 2016-04-01 |
| A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia SAR245409 - Lymphoma | Phase 2 | Completed | Sanofi | 167 | 2011-10-01 | 2016-03-17 |
| Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor) - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Completed | EMD Serono | 146 | 2011-05-01 | 2017-03-07 |
| Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection XL765 (SAR245409), XL147 (SAR245408) - Glioblastoma, Astrocytoma, Grade IV | Phase 1 | Completed | Sanofi | 40 | 2011-01-01 | 2012-07-27 |
| Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara) - Breast Cancer | Phase 1 / Phase 2 | Completed | Sanofi | 72 | 2010-06-01 | 2016-06-03 |
| A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas XL765 (SAR245409), Temozolomide - Mixed Gliomas, Malignant Gliomas | Phase 1 | Completed | Sanofi | 54 | 2008-08-01 | 2013-04-10 |
| Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors XL765 (SAR245409), erlotinib - Cancer, Non-Small Cell Lung Cancer | Phase 1 | Completed | Sanofi | 80 | 2008-08-01 | 2012-02-03 |
| Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors XL765 (SAR245409) - Cancer | Phase 1 | Completed | Sanofi | 83 | 2007-06-01 | 2013-05-30 |
Neoplasms (4) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Glioblastoma (2) · Colorectal Neoplasms (1) · Glioma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Mantle-Cell (1) · Melanoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Sanofi (9) · EMD Serono (2)
United States (11) · Spain (5) · France (4) · Belgium (3) · Australia (2) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1)
2008 (1)